e-learning
resources
ERJ
2009
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Statins in lymphangioleiomyomatosis: a word of caution
El-Chemaly S., Taveira-DaSilva A., Stylianou M. P., Moss J.
Source:
Eur Respir J 2009; 33: 513-514
Journal Issue:
August
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
El-Chemaly S., Taveira-DaSilva A., Stylianou M. P., Moss J.. Statins in lymphangioleiomyomatosis: a word of caution. Eur Respir J 2009; 33: 513-514
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Lymphangioleiomyomatosis (LAM)
Rare interstitial lung diseases (LAM, LHC, alveolar proteinosis, eosinophilic pneumonias)
The large airway lesions of lymphangioleiomyomatosis: Pathological and radiological analysis
Related content which might interest you:
Goal-oriented therapy in pulmonary veno-occlusive disease: a word of caution
Source: Eur Respir J 2009; 34: 1204-1206
Year: 2009
Clinical trials in idiopathic pulmonary fibrosis: a word of caution concerning choice of outcome measures
Source: Eur Respir J 2005; 26: 755-758
Year: 2005
Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution
Source: Eur Respir J, 55 (6) 1902418; 10.1183/13993003.02418-2019
Year: 2020
Doxycycline in lymphangioleiomyomatosis: not all questions are answered
Source: Eur Respir J 2014; 43: 1538
Year: 2014
Doxycycline in lymphangioleiomyomatosis: not all questions are answered
Source: Eur Respir J 2014; 43: 1536-1537
Year: 2014
Pulmonary hypertension: what can we learn from studies?
Source: International Congress 2015 – Practising personalised medicine: why, when, and how?
Year: 2015
Pulmonary hypertension in ILDs: novel therapeutic data
Source: International Congress 2019 – Lungs in the fog
Year: 2019
Idiopathic pulmonary fibrosis trials: recommendations for the jury
Source: Eur Respir J 2011; 38: 1002-1004
Year: 2011
Beta-blockers in COPD: time for reappraisal
Source: Eur Respir J 2016; 48: 880-888
Year: 2016
Learning from registries in pulmonary arterial hypertension: pitfalls and recommendations
Source: Eur Respir Rev, 28 (154) 190050; 10.1183/16000617.0050-2019
Year: 2019
Pulmonary hypertension: new guidelines for therapy
Source: Annual Congress 2007 - PG19 - Pulmonary vascular disorders: diagnosis and treatment
Year: 2007
The changing face of a rare disease: lymphangioleiomyomatosis
Source: Eur Respir J 2015; 46: 1471-1485
Year: 2015
Interventional treatment of pulmonary hypertension: where are we now?
Source: Virtual Congress 2020 – Breathing disorders and cardiovascular diseases
Year: 2020
Presentation by an expert: Pulmonary hypertension: a taste of autoimmunity?
Source: Lung Science Conference 2014 - Lung Inflammation and Immunity
Year: 2014
Late Breaking Abstract: Non-steroid agents for idiopathic pulmonary fibrosis: A systematic review
Source: Annual Congress 2010 - Clinical issues in diffuse parenchymal lung disease
Year: 2010
Making the diagnosis of acute pulmonary embolism: what do the guidelines say?
Source: ERS Course 2020 - Pulmonary hypertension and pulmonary vascular disease
Year: 2020
Oral presentation: Potential of ACE2 as a therapeutic target for pulmonary hypertension
Source: Lung Science Conference 2010 - Biology of gene-environment interactions in the lung
Year: 2010
Pulmonary hypertension therapy and COPD: still many questions to be answered
Source: Eur Respir J 2009; 33: 449
Year: 2009
Pulmonary nodules – incidental findings can we wait?
Source: International Congress 2018 – Lung cancer screening and management of solitary pulmonary nodules
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept